EUVIMEDEUVIMED entdecken
Multizentrische Studie

Splenic stromal sarcomas in dogs: post splenectomy outcomes with and without adjuvant chemotherapy

J Morey iD, J Yu, L Brockley

Australian Veterinary Journal · 2025

DOI: 10.1111/avj.70035 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Australian Veterinary Journal, 2025. Verfasst von J Morey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Vetcare, Kensington, Victoria, Australia. Hauptthemen laut MEDLINE: Dog Diseases, Splenectomy, Splenic Neoplasms, Sarcoma. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Stromal sarcomas are rare canine primary splenic tumors. Previous studies assessing outcomes in dogs with these tumors are limited by small sample sizes, with few dogs receiving adjuvant therapy, leaving the role of chemotherapy in these tumors unproven.

Methods

The aim of this multi‐institutional, retrospective study was to compare outcomes for a larger number of dogs diagnosed with splenic stromal sarcomas, with a particular focus on the effectiveness of adjuvant therapy. Dogs with a histopathological diagnosis of splenic stromal sarcomas were enrolled. Outcomes were compared between dogs that received chemotherapy following splenectomy and those that did not. Furthermore, dogs were categorized based on the type of chemotherapy: a doxorubicin‐based protocol versus a low‐dose metronomic protocol, and outcomes were compared. Secondary aims were to reassess two previously identified prognostic factors: mitotic count (MC) and the presence of metastasis.

Results

A total of 115 dogs were included in the study. The median survival time using all dogs was 8.4 months. Of 115 dogs, 60 received adjuvant therapy post‐splenectomy, of which 37 received a doxorubicin‐based protocol. The use of adjuvant chemotherapy did not improve survival times in dogs with splenic stromal sarcoma. However, MC and the presence of metastasis at diagnosis were prognostic factors for death due to splenic sarcoma. For cases where the MC was ≥9 per 10 hpf, the hazard ratio was 2.27 (95% CI 1.16–4.45). For cases where there was evidence of metastasis at diagnosis, the hazard ratio was 2.19 (95% CI 1.05–4.58). Of 112 dogs staged at diagnosis, 16 had confirmed metastases. An additional 28 dogs developed metastases on repeat staging tests during the study.

Conclusions

The use of adjuvant chemotherapy did not result in improved outcomes. MC and the presence of metastasis at diagnosis were prognostic factors for death due to splenic sarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesSplenectomySplenic NeoplasmsSarcomaAnimalsDogsRetrospective StudiesChemotherapy, AdjuvantMaleFemaleDoxorubicinTreatment Outcome

Stichwörter der Autor:innen

Splenic stromal sarcomasdoxorubicinmetronomic

Substanzen

Doxorubicin

Autor:innen und Institutionen

  • Advanced Vetcare, Kensington, Victoria, Australia.
  • Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: J Morey

Zitieren

APA

Morey, J., Yu, J., & Brockley, L. (2025). Splenic stromal sarcomas in dogs: post splenectomy outcomes with and without adjuvant chemotherapy. Australian Veterinary Journal. https://doi.org/10.1111/avj.70035

Vancouver

Morey J, Yu J, Brockley L. Splenic stromal sarcomas in dogs: post splenectomy outcomes with and without adjuvant chemotherapy. Australian Veterinary Journal. 2025. doi:10.1111/avj.70035

BibTeX
@article{Morey2025,
  author = {Morey, J and Yu, J and Brockley, L},
  title = {Splenic stromal sarcomas in dogs: post splenectomy outcomes with and without adjuvant chemotherapy},
  journal = {Australian Veterinary Journal},
  year = {2025},
  doi = {10.1111/avj.70035}
}
Kostenlos starten →